Your browser is no longer supported. Please, upgrade your browser.
Settings
PTGX Protagonist Therapeutics, Inc. daily Stock Chart
PTGX [NASD]
Protagonist Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.21 Insider Own1.40% Shs Outstand22.24M Perf Week-19.63%
Market Cap201.27M Forward P/E- EPS next Y-1.82 Insider Trans-51.53% Shs Float19.96M Perf Month15.73%
Income-24.20M PEG- EPS next Q-0.44 Inst Own- Short Float0.92% Perf Quarter51.09%
Sales42.50M P/S4.74 EPS this Y18.90% Inst Trans14.10% Short Ratio0.54 Perf Half Y-48.75%
Book/sh5.08 P/B1.78 EPS next Y-42.20% ROA-17.30% Target Price14.63 Perf Year-25.82%
Cash/sh5.63 P/C1.61 EPS next 5Y- ROE-24.20% 52W Range5.50 - 23.97 Perf YTD-56.49%
Dividend- P/FCF- EPS past 5Y- ROI-31.40% 52W High-62.24% Beta-
Dividend %- Quick Ratio4.70 Sales past 5Y- Gross Margin- 52W Low64.55% ATR0.92
Employees62 Current Ratio4.70 Sales Q/Q- Oper. Margin-60.90% RSI (14)54.15 Volatility12.13% 10.80%
OptionableNo Debt/Eq0.00 EPS Q/Q54.00% Profit Margin-56.90% Rel Volume0.30 Prev Close8.58
ShortableYes LT Debt/Eq0.00 EarningsAug 14 AMC Payout- Avg Volume340.34K Price9.05
Recom2.00 SMA207.49% SMA5018.10% SMA200-32.27% Volume101,090 Change5.48%
Jan-29-18Initiated Stifel Buy $32
Jul-21-17Initiated BTIG Research Buy $36
Aug-08-18 11:21AM  Protagonist Stock Jumps 58% After Re-Review of Test Results InvestorPlace
Aug-07-18 06:00PM  Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:57PM  Protagonist Therapeutics: 2Q Earnings Snapshot Associated Press
04:01PM  Protagonist Therapeutics Reports Second Quarter 2018 Financial Results PR Newswire
08:00AM  Todays Research Reports on Stocks to Watch: Protagonist Therapeutics and Intercept Pharmaceuticals ACCESSWIRE
Aug-06-18 07:01AM  Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis PR Newswire +58.63%
07:00AM  Protagonist Therapeutics Secures $22 Million Equity Financing PR Newswire
Aug-01-18 07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Protagonist Therapeutics, HD Supply, BIOHAVEN PHARM, Big Lots, Clean Energy Fuels, and H&E Equipment Services New Research Emphasizes Economic Growth GlobeNewswire
Jun-18-18 07:00AM  Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting PR Newswire
Jun-06-18 07:00AM  Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference PR Newswire
Jun-01-18 07:00AM  Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
May-24-18 04:30PM  Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer PR Newswire
May-22-18 07:30AM  Report: Developing Opportunities within Integer, Sykes Enterprises, Protagonist Therapeutics, Egalet, Watsco, and Extra Space Storage Future Expectations, Projections Moving into 2018 GlobeNewswire
May-17-18 10:14AM  Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association PR Newswire -7.13%
May-16-18 08:00AM  Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors PR Newswire
May-09-18 05:16PM  Protagonist Therapeutics: 1Q Earnings Snapshot Associated Press
04:02PM  Protagonist Therapeutics Reports First Quarter 2018 Financial Results PR Newswire
May-03-18 08:00AM  Protagonist Therapeutics Announces Oral Presentation Accepted for Digestive Diseases Week Conference PR Newswire
Apr-13-18 08:18AM  Protagonist Therapeutics (PTGX) Enters Oversold Territory Zacks
Mar-28-18 05:02PM  Biotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion Zacks -6.31%
08:25AM  Recent Analysis Shows ICU Medical, Motorcar Parts of America, Protagonist Therapeutics, A. Schulman, PennantPark Investment, and H&E Equipment Services Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-27-18 10:08AM  Protagonist Therapeutics Stalls Ulcerative Colitis Study Zacks
Mar-26-18 04:31PM  Why KB Home, Longfin, and Protagonist Therapeutics Slumped Today Motley Fool -57.17%
11:45AM  Why Protagonist Therapeutics, Inc. Is Imploding Today Motley Fool
06:45AM  Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis PR Newswire
Mar-09-18 08:00AM  Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference PR Newswire +14.09%
Mar-08-18 06:26PM  Edited Transcript of PTGX earnings conference call or presentation 7-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-07-18 04:58PM  Protagonist Therapeutics posts 4Q loss Associated Press
04:02PM  Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results PR Newswire
12:00PM  Protagonist Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
06:43AM  Analysts Expect Breakeven On The Horizon For Protagonist Therapeutics Inc (NASDAQ:PTGX) Simply Wall St.
Mar-06-18 04:30PM  FDA Grants Orphan Drug Designation for Protagonist Therapeutics' PTG-300 for the Treatment of Beta-Thalassemia PR Newswire
Mar-01-18 04:00PM  Protagonist Therapeutics to Participate in the Barclay's Global Healthcare Conference PR Newswire
07:00AM  Protagonist to Announce Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018; Year-End Update Call to Follow PR Newswire
Jan-31-18 08:00AM  Protagonist Therapeutics to Participate in the Leerink Partners 7th Annual Global Healthcare Conference PR Newswire
Jan-29-18 12:14PM  Protagonist Therapeutics 'Poised For Upside,' Stifel Says Benzinga +13.10%
Jan-25-18 07:40AM  Analysis: Positioning to Benefit within AllianceBernstein Holding, Motorcar Parts of America, Aegion, Zix, Workiva, and Protagonist Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-04-18 08:00AM  Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300 PR Newswire
Dec-15-17 09:12AM  The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals Zacks
Dec-14-17 06:31AM  Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors PR Newswire
06:30AM  Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 PR Newswire
Dec-04-17 08:00AM  Protagonist Therapeutics to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference PR Newswire -8.21%
Nov-20-17 07:25AM  Protagonist Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTGX-US : November 20, 2017 Capital Cube +6.67%
Nov-10-17 01:24PM  Protagonist Therapeutics, Inc. Value Analysis (NASDAQ:PTGX) : November 10, 2017 Capital Cube
Nov-09-17 08:00AM  Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200 PR Newswire
07:19AM  Protagonist Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTGX-US : November 9, 2017 Capital Cube
Nov-06-17 04:21PM  Protagonist Therapeutics posts 3Q loss Associated Press
04:01PM  Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
Nov-01-17 04:17PM  Protagonist Therapeutics to Present at the Stifel 2017 Healthcare Conference PR Newswire
Oct-26-17 08:48AM  Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics Zacks
Oct-11-17 10:25PM  Protagonist Therapeutics Prices Public Offering of Common Stock PR Newswire
04:01PM  Protagonist Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Sep-20-17 08:00AM  Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 PR Newswire
Sep-14-17 12:38PM  /C O R R E C T I O N -- Protagonist Therapeutics, Inc./ PR Newswire +5.13%
Sep-11-17 04:01PM  Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire
Aug-24-17 04:01PM  Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment PR Newswire +9.42%
Aug-08-17 04:16PM  Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights PR Newswire
Jun-08-17 08:00AM  Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors PR Newswire
Jun-07-17 05:01PM  A small biotech wants to disrupt billion-dollar injectable drug markets with a single pill Business Insider
May-31-17 10:40AM  Why Analysts Think Protagonist Therapeutics Could Still More Than Double After the News 24/7 Wall St. -5.50%
May-30-17 06:25PM  Protagonist Therapeutics Inks License Pact With Johnson & Johnson's Janssen TheStreet.com +43.80%
09:30AM  Why Protagonist Therapeutics Shares Are Climbing 24/7 Wall St.
07:00AM  Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease PR Newswire
May-25-17 08:00AM  Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 PR Newswire -5.60%
May-24-17 08:00AM  Protagonist Therapeutics Receives $1.34 Million SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist Activity PR Newswire -7.71%
May-10-17 04:46PM  Protagonist Therapeutics posts 1Q loss Associated Press
04:01PM  Protagonist Therapeutics Reports First Quarter 2017 Financial Results PR Newswire
May-04-17 05:23PM  Key Patent Issues Covering Protagonist Therapeutics' Oral Peptide IL-23 Receptor Antagonists, including the Development Candidate PTG-200 PR Newswire
Apr-20-17 04:21PM  Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week PR Newswire
Mar-11-17 01:04PM  PROTAGONIST THERAPEUTICS, INC Financials
Mar-09-17 08:00AM  Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference PR Newswire
Mar-07-17 05:44PM  Protagonist Therapeutics posts 4Q loss Associated Press
04:36PM  PROTAGONIST THERAPEUTICS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results PR Newswire
Mar-02-17 08:00AM  Protagonist Therapeutics to Present at the Barclays Global Healthcare Conference PR Newswire
Feb-17-17 06:00AM  Protagonist Therapeutics Presents Data on Oral Peptide Drug Candidates at European Crohn's and Colitis Organization (ECCO) Congress PR Newswire
Feb-09-17 04:29PM  PROTAGONIST THERAPEUTICS, INC Files SEC form 8-K, Change in Directors or Principal Officers -6.09%
Feb-01-17 08:00AM  Protagonist Therapeutics to Participate in the Leerink Partners 6th Annual Global Healthcare Conference PR Newswire
Jan-17-17 08:00AM  Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis PR Newswire
Jan-05-17 08:00AM  Key Patent is Issued Covering Protagonist Therapeutics' Alpha4Beta7 Integrin Peptide Inhibitors including Oral Drug Candidate PTG-100 PR Newswire
Dec-28-16 11:06AM  Here are the Bay Area's IPO winners and losers for 2016 at bizjournals.com
11:06AM  Here are the Bay Area's IPO winners and losers for 2016 American City Business Journals
Dec-14-16 05:09AM  How Corenergy Infrastructure Trust Inc (CORR) Stacks Up Against Its Peers at Insider Monkey
Nov-14-16 05:50PM  PROTAGONIST THERAPEUTICS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:15PM  Protagonist Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
Oct-27-16 07:30AM  [$$] Davis's Take: Will IPO Exit Strategy Overtake M&A in 2017? at The Wall Street Journal -7.89%
Oct-20-16 05:25PM  Supersized IPO charges up S.F. med device maker's first day at bizjournals.com
04:35PM  Latest Bay Area IPO stock jumps after upsized offering raises $107M at bizjournals.com
Oct-13-16 06:22PM  Protagonist Therapeutics to Present Phase 1 Clinical and Preclinical Data on PTG-100 at UEG Week, Vienna PR Newswire
Sep-15-16 04:10PM  PROTAGONIST THERAPEUTICS, INC Files SEC form 10-Q, Quarterly Report
Aug-26-16 04:16AM  Protagonist Therapeutics Inc (PTGX): RA Capital Management Acquires 6.8% Stake at Insider Monkey
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis. It is also developing an oral peptide targeting a GI condition other than IBD. The company was founded in 2006 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CANAAN X L.P.10% OwnerMay 17Sale6.0938,968237,3582,116,552May 21 04:34 PM
CANAAN X L.P.10% OwnerMay 16Sale6.4629,441190,0712,155,520May 16 05:16 PM
CANAAN X L.P.10% OwnerMay 15Sale6.4857,715374,0802,184,961May 16 05:16 PM
CANAAN X L.P.10% OwnerMay 14Sale6.3777,591494,2242,242,676May 16 05:16 PM
PATEL DINESH V PH DPresident and CEOMay 10Option Exercise1.1613,51615,679265,779May 11 06:50 PM
PATEL DINESH V PH DPresident and CEOApr 02Option Exercise1.1620,00023,200252,263Apr 03 05:17 PM
PATEL DINESH V PH DPresident and CEOMar 26Option Exercise0.8711,2989,829232,263Mar 28 05:20 PM
CANAAN X L.P.10% OwnerMar 23Sale20.7159,9501,241,3252,320,267Mar 26 04:25 PM
CANAAN X L.P.10% OwnerMar 22Sale20.624,75998,1332,380,217Mar 22 05:33 PM
CANAAN X L.P.10% OwnerMar 21Sale20.6117,699364,7272,384,976Mar 22 05:33 PM
CANAAN X L.P.10% OwnerMar 20Sale20.6117,060351,5382,402,675Mar 22 05:33 PM
CANAAN X L.P.10% OwnerMar 19Sale20.5713,439276,4462,419,735Mar 19 05:22 PM
CANAAN X L.P.10% OwnerMar 16Sale20.516,926142,0632,433,174Mar 19 05:22 PM
CANAAN X L.P.10% OwnerMar 15Sale20.6411,751242,5212,440,100Mar 15 04:55 PM
CANAAN X L.P.10% OwnerMar 14Sale20.772004,1542,451,851Mar 15 04:55 PM
CANAAN X L.P.10% OwnerMar 13Sale20.841,20425,0942,452,051Mar 15 04:55 PM
Liu David YChief Scientific OfficerMar 12Option Exercise4.213,50014,73518,528Mar 13 04:48 PM
Liu David YChief Scientific OfficerMar 12Sale21.293,50074,50015,028Mar 13 04:48 PM
Liu David YChief Scientific OfficerMar 02Option Exercise1.898751,65414,197Mar 02 07:17 PM
Liu David YChief Scientific OfficerMar 02Sale20.0087517,50013,322Mar 02 07:17 PM
Liu David YChief Scientific OfficerJan 16Option Exercise1.898751,6544,697Jan 17 04:34 PM
Liu David YChief Scientific OfficerJan 16Sale20.0087517,5003,822Jan 17 04:34 PM
Shames Richard S.Chief Medical OfficerDec 22Option Exercise4.213,52914,8573,529Dec 27 02:07 PM
Shames Richard S.Chief Medical OfficerDec 22Sale20.503,52972,3450Dec 27 02:07 PM
PATEL DINESH V PH DPresident and CEODec 21Option Exercise1.898,21015,517198,647Dec 21 07:54 PM
PATEL DINESH V PH DPresident and CEODec 21Sale19.568,210160,570190,437Dec 21 07:54 PM
PATEL DINESH V PH DPresident and CEODec 20Option Exercise1.891,7903,383192,227Dec 20 09:28 PM
PATEL DINESH V PH DPresident and CEODec 20Sale19.551,79034,987190,437Dec 20 09:28 PM
O'Neil Thomas P.Chief Financial OfficerDec 18Option Exercise2.698,00021,4808,000Dec 20 09:08 PM
Liu David YChief Scientific OfficerDec 18Option Exercise1.898751,6544,697Dec 20 09:13 PM
Liu David YChief Scientific OfficerDec 18Sale20.0087517,5003,822Dec 20 09:13 PM
O'Neil Thomas P.Chief Financial OfficerDec 18Sale20.008,000160,0000Dec 20 09:08 PM
Liu David YChief Scientific OfficerNov 30Sale20.0087517,5003,822Dec 01 06:56 PM
Liu David YChief Scientific OfficerNov 13Option Exercise3.057,00021,3507,322Nov 15 07:14 PM
Liu David YChief Scientific OfficerNov 13Sale16.977,000118,7613,822Nov 15 07:14 PM
Shames Richard S.Chief Medical OfficerOct 05Option Exercise4.212,0178,4922,017Oct 10 07:04 PM
Shames Richard S.Chief Medical OfficerOct 05Sale19.002,01738,3230Oct 10 07:04 PM
Shames Richard S.Chief Medical OfficerSep 12Sale14.313,68752,7530Sep 12 07:50 PM
Shames Richard S.Chief Medical OfficerAug 29Option Exercise4.211,5126,3663,377Aug 30 07:08 PM
Shames Richard S.Chief Medical OfficerAug 29Sale17.001,51225,7041,865Aug 30 07:08 PM
Liu David YChief Scientific OfficerAug 28Option Exercise4.213,50014,7355,500Aug 29 07:48 PM
Liu David YChief Scientific OfficerAug 28Sale15.003,50052,5002,000Aug 29 07:48 PM